Turn Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TTRX$9.92+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
| Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in · Subscription · Accumulated · Stockholders’ Equity | |||||||
| Shares* · Amount* · Capital · Receivable · Deficit · (Deficit) | |||||||
| As at December 31, 2024 | 26,845,690 | $2,685 | $19,015,896 | $ | - | $(19,196,013) | $(177,432) |
| Issuance of common stock under Regulation Crowdfunding, net of issuance costs | 215,972 | 22 | 777,781 | - | - | 777,803 | |
| Issuance of common stock under Regulation A+, net of issuance costs | 83,610 | 8 | 280,484 | (52,699) | - | 227,793 | |
| Issuance of common stock under Regulation D, net of issuance costs | 775,468 | 78 | 2,735,824 | - | - | 2,735,902 | |
| Issuance of stock in exchange for advisory services | 54,466 | 5 | 249,995 | - | - | 250,000 | |
| Issuance of common stock upon exercise of warrants | 47,620 | 4 | 234 | - | - | 238 | |
| Stock-based compensation expense | - | - | 162,865 | - | - | 162,865 | |
| Net loss | - | - | - | - | (3,473,150) | (3,473,150) | |
| As at September 30, 2025 | 28,022,826 | $2,802 | $23,223,079 | $(52,699) | $(22,669,163) | $504,019 | |
| Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in · Subscription · Accumulated · Stockholders’ Equity | |||||||
| Shares* · Amount* · Capital · Receivable · Deficit · (Deficit) | |||||||
| As at December 31, 2023 | 26,494,482 | $2,649 | $17,510,717 | $ | - | $(17,427,598) | $85,768 |
| Issuance of common stock under Regulation Crowdfunding, net of issuance costs | 196,024 | 20 | 630,178 | - | - | 630,198 | |
| Stock-based compensation expense | - | - | 315,020 | - | - | 315,020 | |
| Net loss | - | - | - | - | (1,445,285) | (1,445,285) | |
| As at September 30, 2024 | 26,690,506 | $2,669 | $18,455,915 | $ | - | $(18,872,883) | $(414,299) |
| * | Retroactively adjusted for 2-for-1 forward stock split. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.